116 recruiting, 88 completed, 79 active not recruiting, 29 terminated. 348 Phase 3, 40 Phase 2.
Follow pembrolizumab: new trials by email Literature Review of pembrolizumab trials Research Report on pembrolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer EG-007, Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection, Lenvatinib Capsules - Advanced Endometrial Cancer | Phase 3 | Not yet recruiting | Evergreen Therapeutics, Inc. | 450 | 2026-12-01 | 2025-12-08 |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer enfortumab vedotin and pembrolizumab (EV/P) - Advanced Bladder Cancer | Phase 3 | Not yet recruiting | Guliz Ozgun | 224 | 2026-11-01 | 2026-10-01 |
| Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden Tislelizumab, Tislelizumab Combined With Chemotherapy, Pembrolizumab - Non-small Cell Lung Cancer Metastatic | Phase 3 | Not yet recruiting | AIO-Studien-gGmbH | 230 | 2026-10-30 | 2026-10-26 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-20 | 2026-09-21 |
| Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer PF-08634404, Pembrolizumab, Standard of Care Chemotherapy - Endometrial Neoplasms, Endometrial Cancer | Phase 3 | Recruiting | Pfizer | 600 | 2026-10-14 | 2026-10-30 |
| A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) Divarasib, Pembrolizumab, Nivolumab - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Hoffmann-La Roche | 400 | 2026-10-06 | 2026-10-13 |
| A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) Mocertatug rezetecan, Dostarlimab, Pembrolizumab - Neoplasms, Endometrial | Phase 3 | Recruiting | GlaxoSmithKline | 610 | 2026-09-24 | 2026-10-15 |
| A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants ABBV-1480, Pembrolizumab, Carboplatin - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 940 | 2026-09-22 | 2026-10-20 |
| Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy, PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy - Squamous Cell Carcinoma of Head and Neck | Phase 3 | Recruiting | Ji Dongmei | 316 | 2026-09-15 | 2026-10-02 |
| A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma Ivonescimab Dose 1, enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC) | Phase 2 / Phase 3 | Recruiting | Summit Therapeutics | 800 | 2026-09-10 | 2026-09-11 |
| A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets - Triple Negative Breast Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1000 | 2026-09-02 | 2026-09-09 |
| NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy - Breast Cancer, Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Women's Cancer Study Group GmbH | 765 | 2026-08-30 | 2026-08-05 |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer | Phase 3 | Recruiting | Exelixis | 600 | 2026-08-25 | 2026-09-21 |
Showing 20 of 348. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (102) · Parkinson Disease 4, Autosomal Dominant Lewy Body (99) · Lung Neoplasms (27) · Squamous Cell Carcinoma of Head and Neck (25) · Melanoma (22) · Head and Neck Neoplasms (17) · Neoplasm Metastasis (15) · Triple Negative Breast Neoplasms (15) · Breast Neoplasms (14) · Stomach Neoplasms (13) · Carcinoma, Renal Cell (12) · Endometrial Neoplasms (11) · Urinary Bladder Neoplasms (11) · Carcinoma (10) · Carcinoma, Transitional Cell (10)
Merck Sharp & Dohme LLC (128) · National Cancer Institute (NCI) (17) · AstraZeneca (13) · GlaxoSmithKline (6) · Hoffmann-La Roche (6) · Incyte Corporation (5) · Alliance for Clinical Trials in Oncology (4) · Amgen (4) · Astellas Pharma Global Development, Inc. (4) · Daiichi Sankyo (4) · Eli Lilly and Company (4) · Hunan Province Tumor Hospital (4) · Pfizer (4) · SWOG Cancer Research Network (4) · Bristol-Myers Squibb (3)
United States (216) · France (171) · Spain (171) · Germany (162) · South Korea (161) · Italy (158) · Japan (156) · China (155) · Canada (154) · United Kingdom (153) · Australia (143) · Poland (141) · Brazil (128) · Turkey (Türkiye) (128) · Taiwan (127)
Mark Jones, MD (5) · Yongchang Zhang, MD (3)
PMID 31395089, PMID 33300372, PMID 37465924, PMID 38642841, PMID 32305010, PMID 35101941, PMID 39230120, PMID 29658430, PMID 33231285, PMID 33792646, PMID 34008425, PMID 35073727, PMID 35367007, PMID 35421228, PMID 36793385, PMID 37037952, PMID 37146227, PMID 37348035, PMID 37699333, PMID 38159809, PMID 39306585, PMID 40037029, PMID 40117530, PMID 40486134, PMID 40498298, PMID 40966692, PMID 41747891, PMID 41811823, PMID 42167105, PMID 42176183, PMID 23886301, PMID 23957516, PMID 25891173, PMID 25979390, PMID 26454620, PMID 26712084, PMID 27718847, PMID 28212060, PMID 28822576, PMID 28987768, PMID 29129441, PMID 29439857, PMID 29562804, PMID 29590008, PMID 29658856, PMID 29880231, PMID 29896663, PMID 30096704, PMID 30202085, PMID 30280635
2023 (66), 2018 (26), 2017 (14), 2019 (14), 2025 (14), 2015 (12), 2016 (12), U10CA180820 (10), 2014 (8), U10CA180888 (6), U10CA180821 (4), U10CA180868 (4), P30CA012197 (1)